Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of LLDT-8 ((5R)-5-hydroxytriptolide) to preparation of drug for treating non-alcoholic fatty liver disease

A fatty liver disease and drug technology, applied in the field of pharmacotherapeutics, can solve the problems of incomplete elucidation of the pathogenesis and no effective marketed drugs for treatment.

Active Publication Date: 2020-10-27
SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since the occurrence of NAFLD is closely related to metabolic syndrome such as diabetes, obesity, and hypertension, its pathogenesis has not yet been fully elucidated, so there is no effective marketed drug for the treatment of this disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of LLDT-8 ((5R)-5-hydroxytriptolide) to preparation of drug for treating non-alcoholic fatty liver disease
  • Application of LLDT-8 ((5R)-5-hydroxytriptolide) to preparation of drug for treating non-alcoholic fatty liver disease
  • Application of LLDT-8 ((5R)-5-hydroxytriptolide) to preparation of drug for treating non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0118] Example 1: Leitengshu relieves lipid accumulation and damage in the liver of NAFLD model mice

[0119] In the present invention, on the model mice of NAFLD induced by a high-fat and high-sugar diet, the influence of reitengshu on lipid accumulation and damage in the liver of the model mice is tested. Experiments have shown that Leitenshu can alleviate the lipid accumulation in the liver of NAFLD model mice, reduce the two important indicators of liver function, AST and ALT, and the liver damage caused by ballooning.

[0120] 1. Experimental principle:

[0121] High-fat and high-sugar diet-induced C57BL / 6J is a classic mouse model of NAFLD, which can relatively simulate the main clinical features, biochemical changes and morphological changes of NAFLD [Biomed Res Int. 2015:574832,2015]. The present invention uses this induction scheme as an animal model for evaluating the anti-type 2 diabetes of the compound.

[0122] 2. Experimental materials and methods

[0123] 1) ...

Embodiment 2

[0134] Example 2: Effect of Leitenshu on the types and contents of fatty acids in the liver of NAFLD model mice

[0135] The present invention uses gas chromatography-mass spectrometry to detect the types and contents of fatty acids in the liver of experimental animals, compares the differences in fatty acids between the Leitenshu administration group and the solvent control group, and infers its effect from Leitenshu on liver fatty acid metabolism. Possible mechanism for inhibition of lipid accumulation. The research results show that Leitenshu can significantly reduce the ratio of C16:1 / C16:0 fatty acid and the ratio of C16:0 / C18:2n6 fatty acid, indicating that the activity of SCD-1 and lipid regeneration are inhibited.

[0136] 1. Experimental principle:

[0137] The activity of some lipogenesis-related enzymes can be predicted by the ratio of different products to precursors of fatty acids, for example: the activity of SCD-1 can be characterized by the ratio of C16:1n-7 / C16...

Embodiment 3

[0148] Example 3: The effect of the tissue level test compound Leitenshu on SCD-1 in the liver

[0149] The present invention uses real-time quantitative fluorescent PCR technology to detect the effect of the compound Leitenshu on SCD-1 mRNA in liver tissue. The research results show that: high dose Leitenshu can significantly inhibit the mRNA of SCD-1 in liver tissue.

[0150] 1. Experimental materials and methods:

[0151] (1) RNA extraction from liver tissue: Accurately weigh 10 mg of liver tissue; add two steel beads to a centrifuge tube containing 10 mg of tissue, add 1 ml of Trizol, and homogenize with a homogenizer; centrifuge at 12,000 rpm for 5 min at 4°C, and take Transfer the clear liquid into a new 1.5ml centrifuge tube; add 200μL chloroform, mix by inverting for 2min, let stand for 5min, centrifuge at 12000rpm at 4°C for 10min; take 400μL of the upper aqueous phase into a clean centrifuge tube, add 200μL of absolute ethanol, mix well After that, let it stand for ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of LLDT-8 ((5R)-5-hydroxytriptolide) to preparation of a drug for treating non-alcoholic fatty liver disease. According to the application, the LLDT-8 serving as anSCD-1 transcription inhibitor and / or a fatty acid beta oxidation related gene transcription activator contains PPAR[alpha], ACADL, ACADM, ACOX1 and CPT1A. The LLDT-8 can inhibit mRNA of SCD-1, thereby inhibiting desaturation of fatty acid and inhibiting lipid regeneration; and meanwhile, the LLDT-8 can increase mRNA of fatty acid beta oxidation related genes, so that beta oxidation of fatty acidis increased, the content of beta-hydroxybutyric acid in serum is increased, and finally, lipid accumulation in the liver is inhibited by inhibiting the lipid generation and promoting lipid oxygenolysis.

Description

technical field [0001] The invention relates to the field of drug therapy, in particular to the use of Leitenshu or its pharmaceutical composition in the treatment of non-alcoholic fatty liver disease. Background technique [0002] Triptolide ((5R)-5-hydroxytriptolide, LLDT-8) is a derivative of triptolide (Triptolide), an effective extract from the traditional Chinese medicine Tripterygium wilfordii Hook.f.TWHF. It also has immunosuppressive activity, but Less toxic. Current studies suggest that the anti-inflammatory effect of Leitenshu is mainly through inhibiting the production of Th1 cytokines (IFN-c, IL-2) and inflammatory cytokines (TNF-α, IL-6); reducing the production of nitric oxide (NO) This is achieved through regulatory mechanisms such as production and expression of inducible nitric oxide synthase (iNOS). In addition, Leitenshu has been reported to have anti-tumor biological activity. [0003] [0004] Nonalcoholic fatty liver disease (NAFLD) is a kind of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/585A61P1/16
CPCA61K31/585A61P1/16
Inventor 任进陆姮磊陈静董云霞戚新明李援朝
Owner SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com